Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and Heart Failure

lapatinib has been researched along with Heart Failure in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Colon-Otero, G; Dakhil, S; Dueck, AC; Franco, S; Ghanem-Cañete, I; Jenkins, RB; Johnson, D; Kahanic, S; McCullough, AE; Moreno-Aspitia, A; Northfelt, D; Palmieri, FM; Patel, T; Perez, EA; Rodeheffer, R; Tenner, KS1
Abbruzzi, A; Chen, C; Come, SE; Dang, CT; Hudis, CA; Iyengar, NM; Lehman, R; Lin, N; Morris, PG; Moy, B; Norton, L; Oeffinger, KC; Patil, S; Steingart, R; Winer, EP1
Akgullu, C; Aksun, S; Bilgen, M; Boyacioglu, M; Demirci, B; Eryilmaz, U; Ilgenli, TF; Yalinkilinc, HS1
Byrne, J; Ewer, MS; Koehler, M; Perez, EA; Preston, AJ; Rappold, E1
Perez, EA1
Rowan, K1
Bedard, PL; de Azambuja, E; Piccart-Gebhart, M; Suter, T1
Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A1
Criscitiello, C; de Azambuja, E; de Castro, G; Diaz, M; La Gerche, A; Metzger-Filho, O; Piccart-Gebhart, MJ; Saini, KS1

Reviews

4 review(s) available for lapatinib and Heart Failure

ArticleYear
Cardiac toxicity of ErbB2-targeted therapies: what do we know?
    Clinical breast cancer, 2008, Volume: 8 Suppl 3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Heart; Heart Failure; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab

2008
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
    Targeted oncology, 2009, Volume: 4, Issue:2

    Topics: Adjuvants, Immunologic; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Heart Failure; Humans; Lapatinib; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Ventricular Outflow Obstruction

2009
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab

2011
Targeted therapies in breast cancer: are heart and vessels also being targeted?
    Breast cancer research : BCR, 2012, Jun-19, Volume: 14, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Female; Heart Failure; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Trastuzumab; Ventricular Dysfunction, Left

2012

Trials

2 trial(s) available for lapatinib and Heart Failure

ArticleYear
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
    Breast cancer research and treatment, 2013, Volume: 138, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Treatment Outcome; Ventricular Function, Left

2013
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
    Cancer, 2013, Nov-15, Volume: 119, Issue:22

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Failure; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome

2013

Other Studies

3 other study(ies) available for lapatinib and Heart Failure

ArticleYear
S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers.
    PloS one, 2015, Volume: 10, Issue:12

    Topics: Animals; Antineoplastic Agents; Biomarkers; Catalase; Glutathione; Heart Failure; Lapatinib; Male; Malondialdehyde; Myocardium; Neoplasms; Oxidative Stress; Quinazolines; Rats, Wistar; S100 Proteins; Superoxide Dismutase; Trastuzumab

2015
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Stroke Volume; Ventricular Dysfunction, Left

2008
Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Journal of the National Cancer Institute, 2009, Apr-01, Volume: 101, Issue:7

    Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Female; Heart; Heart Failure; Humans; Lapatinib; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab

2009